Venous thromboembolic disease is considered one of the leading causes of morbi-mortality [1,2]. in oncological patients. Cancer multiplies the risk of thromboembolic events 6- or 7-fold compared to the general population without cancer [3,4], and this risk is greater in certain tumor sites and in people receiving chemotherapy. The incidence of VTE in individuals with pancreatic cancer is high, although it varies widely in the literature [5–23] due, in part, to the differences in the populations studied.
